Strata Critical Medical (NASDAQ:SRTA) Issues Earnings Results

Key Points

• Strata Critical Medical reported mixed quarterly results: revenue rose 50.3% year over year to $74.1 million, adjusted EBITDA reached $9.6 million, and free cash flow hit a record $8.6 million, but EPS of ($0.09) missed the $0.01 consensus estimate.
• Clinical operations were the primary growth driver, increasing 20.3% sequentially and more than 30% on a comparable year-over-year basis. Logistics revenue declined due to seasonal transplant weakness and shorter industry trip distances.
• The company ended the quarter with $41.6 million in cash and short-term investments, authorized a $20 million share repurchase, and reiterated its 2026 financial guidance while pursuing acquisitions.

Strata Critical Medical (NASDAQ:SRTA - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.10), FiscalAI reports. Strata Critical Medical had a net margin of 15.71% and a negative return on equity of 2.97%. The firm had revenue of $74.08 million for the quarter.

Here are the key takeaways from Strata Critical Medical's conference call:

• Q3 results exceeded guidance, with revenue up 50.3% year over year to $74.1 million, adjusted EBITDA rising to $9.6 million, and record free cash flow of $8.6 million. Management reiterated 2026 revenue, adjusted EBITDA, and free-cash-flow guidance.
• The clinical segment grew 20.3% sequentially and more than 30% on a comparable year-over-year basis, even as industry transplant volumes declined seasonally. Management attributed the performance to market-share gains from its integrated organ recovery, perfusion, and logistics offering, with clinical growth expected to lead in 2027.
• Logistics revenue declined 6.9% sequentially and 3.5% year over year, pressured by seasonal transplant weakness and approximately 10% shorter industry trip distances, particularly following changes to lung-allocation rules. The company expects logistics revenue to be roughly flat sequentially in Q4, while clinical drives overall growth.
• Strata ended the quarter with $41.6 million in cash and short-term investments after receiving $15.3 million from its Passenger earnout, with another $27.5 million potentially due in early 2027. The company authorized a $20 million share repurchase while maintaining plans to accelerate acquisitions at targeted mid-single-digit valuation multiples.

Strata Critical Medical Stock Performance

Shares of NASDAQ SRTA traded up $0.24 during trading on Tuesday, hitting $4.53. The company had a trading volume of 410,505 shares, compared to its average volume of 949,200. Strata Critical Medical has a 52 week low of $3.95 and a 52 week high of $6.50. The business's 50-day moving average is $5.07 and its 200 day moving average is $5.21. The company has a market cap of $400.31 million, a P/E ratio of -113.12 and a beta of 2.43.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Strata Critical Medical from a "hold (c)" rating to a "hold (c-)" rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $8.00.

Insider Activity

In other Strata Critical Medical news, Director Reginald Love sold 5,091 shares of the business's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $5.75, for a total transaction of $29,273.25. Following the sale, the director owned 146,481 shares in the company, valued at approximately $842,265.75. The trade was a 3.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 15.50% of the stock is owned by insiders.

Strata Critical Medical Company Profile

Blade Air Mobility, Inc provides air transportation alternatives to the congested ground routes in the United States. It provides its services through charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes. The company was founded in 2014 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.